Synakis is developing novel biomaterial-based treatments for ocular conditions. Created in https://BioRender.com.
Synakis is a pre-clinical biotech startup developing novel biomaterial-based treatments for ocular injuries and diseases, including retinal detachment and glaucoma. Our mission is to restore vision and improve the lives of patients suffering from these conditions.
Synakis’ core technology, SNK-125, is a novel hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous substitute for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Upcoming Events
Want to meet our team and learn more about Synakis? Meet us at these upcoming events:
Ophthalmic Drug Delivery Summit - January 27-29, 2026, San Francisco, CA
Glaucoma 360 - January 30-31, 2026, San Francisco, CA
OBIO Investment Summit - February 3-5, 2026, Toronto, ON
Synakis’ Jonathan Labriola (middle) presented with the 1st place award at ARVO Eye Pitch.
Synakis Awarded Overall Winner at ARVO 2025 Eye Pitch
May 3, 2025
Synakis has won the $25,000 1st place prize as the Overall Winner at the ARVO 2025 Eye Pitch.